Boston Therapeutics Measures the Impact of sugardown® Taken Before Sodas

Posted by Laura Swartz

January 20, 2015 at 11:18 AM

On Tuesday, January 20, 2015, Boston Therapeutics, Inc. (BTHE-OTC) released additional trial results from its Sydney University study that showed consumption of sugardown® tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose, and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown® tablets were found to reduce glucose and fructose levels by up to a total of 20% and insulin levels by up to 14%. Four sugardown® tablets were found to reduce total glucose and fructose levels by up to 28% and insulin levels by up to 18%. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier in January that there was an average reduction in glycemic index (GI) of approximately 10% following soft drink consumption with two sugardown® tablets.

Study Details and Discussion

Read More

Topics: BTHE

Amarantus Acquires Specialized Neuro-Diagnostics Company, DioGenix, Inc.

Posted by Laura Swartz

January 12, 2015 at 12:24 PM

  • Lead Product MSPrecise(R): Clinically Validated, First-In-Class Next-Generation Sequencing (NGS) Assay that Identifies Multiple Sclerosis (MS) at First Clinical Presentation
  • Recent Prospective Study at 13 U.S. Centers of MS Excellence Demonstrated the Significant Diagnostic Accuracy of MSPrecise
  • Platform for Comprehensive Molecular Profiling of Immune-mediated Neurodegenerative Diseases
Read More

Topics: Amarantus

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic